WORCESTER, Mass., Aug. 5, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com) today announced publication of pre-clinical studies conducted to identify vaccine peptides for the potentially pandemic H5N1 avian influenza virus. The report is the result of a collaboration between scientists at Antigen Express, Inc. (www.antigenexpress.com), Generex’s wholly-owned immunotherapeutics subsidiary, and Dr. John Treanor (Professor of Medicine, and of Microbiology and Immunology, Department of Medicine, University of Rochester).
